chart, page-4

Hey there cbzers
just a couple of points i really liked from the report.

"Interactions with these companies have intensified in one case and should further intensify once the results from the clinical trial are available".The Board continues to believe that XToll may be useful in a number of disease states in addition to RA and therefore remains committed to building CBio as an early-stage drug development company in order to exploitany and all commercial opportunities."

Just my opinion but i take this as everyone is getting excited and players are jostling for positions,the 2nd part is the company reassuring us that this is not a takeover but a partnership so we the shareholders can continue to benefit from future developments,,,nice!!!

"Dr Lunngren is the former Executive Director of the European Medicines Agency, the pharmaceutical regulatory body of the European Union"

I would like to know if others like this appointment. Planning on getting XToll into europe,who knows all the in and outs of that ay?,,,some smart people here!!!